Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

389 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors.
Abou Alaiwi S, Nassar AH, Xie W, Bakouny Z, Berchuck JE, Braun DA, Baca SC, Nuzzo PV, Flippot R, Mouhieddine TH, Spurr LF, Li YY, Li T, Flaifel A, Steinharter JA, Margolis CA, Vokes NI, Du H, Shukla SA, Cherniack AD, Sonpavde G, Haddad RI, Awad MM, Giannakis M, Hodi FS, Liu XS, Signoretti S, Kadoch C, Freedman ML, Kwiatkowski DJ, Van Allen EM, Choueiri TK. Abou Alaiwi S, et al. Among authors: signoretti s. Cancer Immunol Res. 2020 Aug;8(8):1075-1084. doi: 10.1158/2326-6066.CIR-19-0866. Epub 2020 Apr 22. Cancer Immunol Res. 2020. PMID: 32321774 Free PMC article.
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Choueiri TK, Regan MM, Rosenberg JE, Oh WK, Clement J, Amato AM, McDermott D, Cho DC, Atkins MB, Signoretti S. Choueiri TK, et al. Among authors: signoretti s. BJU Int. 2010 Sep;106(6):772-8. doi: 10.1111/j.1464-410X.2010.09218.x. Epub 2010 Mar 2. BJU Int. 2010. PMID: 20230385
FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis.
Gan B, Lim C, Chu G, Hua S, Ding Z, Collins M, Hu J, Jiang S, Fletcher-Sananikone E, Zhuang L, Chang M, Zheng H, Wang YA, Kwiatkowski DJ, Kaelin WG Jr, Signoretti S, DePinho RA. Gan B, et al. Among authors: signoretti s. Cancer Cell. 2010 Nov 16;18(5):472-84. doi: 10.1016/j.ccr.2010.10.019. Cancer Cell. 2010. PMID: 21075312 Free PMC article.
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1.
Lin W, Cao J, Liu J, Beshiri ML, Fujiwara Y, Francis J, Cherniack AD, Geisen C, Blair LP, Zou MR, Shen X, Kawamori D, Liu Z, Grisanzio C, Watanabe H, Minamishima YA, Zhang Q, Kulkarni RN, Signoretti S, Rodig SJ, Bronson RT, Orkin SH, Tuck DP, Benevolenskaya EV, Meyerson M, Kaelin WG Jr, Yan Q. Lin W, et al. Among authors: signoretti s. Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13379-86. doi: 10.1073/pnas.1110104108. Epub 2011 Jul 25. Proc Natl Acad Sci U S A. 2011. PMID: 21788502 Free PMC article.
BRAF mutations in metanephric adenoma of the kidney.
Choueiri TK, Cheville J, Palescandolo E, Fay AP, Kantoff PW, Atkins MB, McKenney JK, Brown V, Lampron ME, Zhou M, Hirsch MS, Signoretti S. Choueiri TK, et al. Among authors: signoretti s. Eur Urol. 2012 Nov;62(5):917-22. doi: 10.1016/j.eururo.2012.05.051. Epub 2012 Jun 9. Eur Urol. 2012. PMID: 22727996 Free PMC article.
Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).
Choueiri TK, Cheng S, Qu AQ, Pastorek J, Atkins MB, Signoretti S. Choueiri TK, et al. Among authors: signoretti s. Urol Oncol. 2013 Nov;31(8):1788-93. doi: 10.1016/j.urolonc.2012.07.004. Epub 2012 Nov 7. Urol Oncol. 2013. PMID: 23141780 Free PMC article.
Renal-cell carcinoma: a step closer to a new classification.
Choueiri TK, Pomerantz MM, Signoretti S. Choueiri TK, et al. Among authors: signoretti s. Lancet Oncol. 2013 Feb;14(2):105-7. doi: 10.1016/S1470-2045(12)70599-5. Epub 2013 Jan 16. Lancet Oncol. 2013. PMID: 23333115 No abstract available.
The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.
Choueiri TK, Fay AP, Gagnon R, Lin Y, Bahamon B, Brown V, Rosenberg JE, Hutson TE, Baker-Neblett KL, Carpenter C, Liu Y, Pandite L, Signoretti S. Choueiri TK, et al. Among authors: signoretti s. Clin Cancer Res. 2013 Sep 15;19(18):5218-26. doi: 10.1158/1078-0432.CCR-13-0491. Epub 2013 Jul 23. Clin Cancer Res. 2013. PMID: 23881929 Free PMC article. Clinical Trial.
389 results